News about "Takeda "

US FDA Accepts NDA under Priority Review for Takeda's Zasocitinib

The US Food and Drug Administration (FDA) has accepted Takeda’s New Drug Application (NDA) for zasocitinib under Priority Review (PR) for the treatment of moderate-to-severe plaque psoriasis, potentially redefining expectations for oral treatment.

Takeda | 15/09/2026 | By News Bureau

Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1

Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.

Takeda | 24/08/2026 | By News Bureau |  121

India Approves Takeda's TAK-003 as First Dengue Vaccine

India approves Takeda's TAK-003 as its first dengue vaccine, offering long-term protection against dengue disease and hospitalisation amid rising dengue cases.

Takeda | 22/07/2026 | By News Bureau |  132

Takeda and Indonesia Partner to Expand Access to Plasma-Derived Medicines

Takeda and Indonesia have partnered to strengthen healthcare resilience, expand access to plasma-derived medicines, and establish a national plasma donation ecosystem with an initial USD 30 million investment.

Takeda | 13/07/2026 | By News Bureau |  120

Insilico Medicine and Takeda Collaborate on AI Drug Discovery

Takeda and Insilico Medicine are collaborating to advance Artificial Intelligence (AI)-powered drug discovery, leveraging the Pharma.AI platform to accelerate the development of therapeutics.

Takeda | 02/07/2026 | By News Bureau |  177

Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1

Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.

Takeda | 16/06/2026 | By News Bureau |  132

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Takeda | 08/04/2026 | By News Bureau |  163

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Takeda | 30/03/2026 | By News Bureau |  266

Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1

FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.

Takeda | 11/02/2026 | By News Bureau |  228

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Takeda | 19/12/2025 | By News Bureau |  185